Anti-CD20 monoclonal antibodies: reviewing a revolution

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment...

Descripción completa

Detalles Bibliográficos
Autores principales: Casan, J. M. L., Wong, J., Northcott, M. J., Opat, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Product Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343614/
https://www.ncbi.nlm.nih.gov/pubmed/30096012
http://dx.doi.org/10.1080/21645515.2018.1508624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343614/
https://www.ncbi.nlm.nih.gov/pubmed/30096012
http://dx.doi.org/10.1080/21645515.2018.1508624

Ejemplares similares